Background: Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high and unlikely to affect therapy. The DIPG Biology and Treatment Study (DIPG-BATS) reported here incorporated a surgical biopsy at presentation and stratified subjects to receive FDA-approved agents chosen on the basis of specific biologic targets. Methods: Subjects were eligible for the trial if the clinical features and imaging appearance of a newly diagnosed tumor were consistent with a DIPG. Surgical biopsies were performed after enrollment and prior to definitive treatment. All subjects were treated with conventional external beam radiotherapy with bevacizumab, and then stratified to receive bevacizumab with erlotinib or temozolomide, both agents, or neither agent, based on O6-methylguanine-DNA methyltransferase status and epidermal growth factor receptor expression. Whole-genome sequencing and RNA sequencing were performed but not used for treatment assignment. Results: Fifty-three patients were enrolled at 23 institutions, and 50 underwent biopsy. The median age was 6.4 years, with 24 male and 29 female subjects. Surgical biopsies were performed with a specified technique and no deaths were attributed to the procedure. Two subjects experienced grade 3 toxicities during the procedure (apnea, n = 1; hypertension, n = 1). One subject experienced a neurologic deficit (left hemiparesis) that did not fully recover. Of the 50 tumors biopsied, 46 provided sufficient tissue to perform the study assays (92%, two-stage exact binomial 90% CI: 83%-97%). Conclusions: Surgical biopsy of DIPGs is technically feasible, associated with acceptable risks, and can provide biologic data that can inform treatment decisions.
Background: Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high and unlikely to affect therapy. The DIPG Biology and Treatment Study (DIPG-BATS) reported here incorporated a surgical biopsy at presentation and stratified subjects to receive FDA-approved agents chosen on the basis of specific biologic targets. Methods: Subjects were eligible for the trial if the clinical features and imaging appearance of a newly diagnosed tumor were consistent with a DIPG. Surgical biopsies were performed after enrollment and prior to definitive treatment. All subjects were treated with conventional external beam radiotherapy with bevacizumab, and then stratified to receive bevacizumab with erlotinib or temozolomide, both agents, or neither agent, based on O6-methylguanine-DNA methyltransferase status and epidermal growth factor receptor expression. Whole-genome sequencing and RNA sequencing were performed but not used for treatment assignment. Results: Fifty-three patients were enrolled at 23 institutions, and 50 underwent biopsy. The median age was 6.4 years, with 24 male and 29 female subjects. Surgical biopsies were performed with a specified technique and no deaths were attributed to the procedure. Two subjects experienced grade 3 toxicities during the procedure (apnea, n = 1; hypertension, n = 1). One subject experienced a neurologic deficit (left hemiparesis) that did not fully recover. Of the 50 tumors biopsied, 46 provided sufficient tissue to perform the study assays (92%, two-stage exact binomial 90% CI: 83%-97%). Conclusions: Surgical biopsy of DIPGs is technically feasible, associated with acceptable risks, and can provide biologic data that can inform treatment decisions.
Authors: Barbara S Paugh; Alberto Broniscer; Chunxu Qu; Claudia P Miller; Junyuan Zhang; Ruth G Tatevossian; James M Olson; J Russell Geyer; Susan N Chi; Nasjla Saba da Silva; Arzu Onar-Thomas; Justin N Baker; Amar Gajjar; David W Ellison; Suzanne J Baker Journal: J Clin Oncol Date: 2011-09-19 Impact factor: 44.544
Authors: Richard J Gilbertson; D Ashley Hill; Roberto Hernan; Mehmet Kocak; Russell Geyer; Jim Olson; Amar Gajjar; Lisa Rush; Ronald L Hamilton; Sydney D Finkelstein; Ian F Pollack Journal: Clin Cancer Res Date: 2003-09-01 Impact factor: 12.531
Authors: Thomas Roujeau; Guilherme Machado; Matthew R Garnett; Catherine Miquel; Stephanie Puget; Birgit Geoerger; Jacques Grill; Nathalie Boddaert; Federico Di Rocco; Michel Zerah; Christian Sainte-Rose Journal: J Neurosurg Date: 2007-07 Impact factor: 5.115
Authors: Tene A Cage; Sonia P Samagh; Sabine Mueller; Theodore Nicolaides; Daphne Haas-Kogan; Michael Prados; Anu Banerjee; Kurtis I Auguste; Nalin Gupta Journal: Childs Nerv Syst Date: 2013-05-11 Impact factor: 1.475
Authors: Gang Wu; Alexander K Diaz; Barbara S Paugh; Sherri L Rankin; Bensheng Ju; Yongjin Li; Xiaoyan Zhu; Chunxu Qu; Xiang Chen; Junyuan Zhang; John Easton; Michael Edmonson; Xiaotu Ma; Charles Lu; Panduka Nagahawatte; Erin Hedlund; Michael Rusch; Stanley Pounds; Tong Lin; Arzu Onar-Thomas; Robert Huether; Richard Kriwacki; Matthew Parker; Pankaj Gupta; Jared Becksfort; Lei Wei; Heather L Mulder; Kristy Boggs; Bhavin Vadodaria; Donald Yergeau; Jake C Russell; Kerri Ochoa; Robert S Fulton; Lucinda L Fulton; Chris Jones; Frederick A Boop; Alberto Broniscer; Cynthia Wetmore; Amar Gajjar; Li Ding; Elaine R Mardis; Richard K Wilson; Michael R Taylor; James R Downing; David W Ellison; Jinghui Zhang; Suzanne J Baker Journal: Nat Genet Date: 2014-04-06 Impact factor: 38.330
Authors: Kathryn R Taylor; Alan Mackay; Nathalène Truffaux; Yaron Butterfield; Olena Morozova; Cathy Philippe; David Castel; Catherine S Grasso; Maria Vinci; Diana Carvalho; Angel M Carcaboso; Carmen de Torres; Ofelia Cruz; Jaume Mora; Natacha Entz-Werle; Wendy J Ingram; Michelle Monje; Darren Hargrave; Alex N Bullock; Stéphanie Puget; Stephen Yip; Chris Jones; Jacques Grill Journal: Nat Genet Date: 2014-04-06 Impact factor: 38.330
Authors: Flor M Mendez; Felipe J Núñez; Maria B Garcia-Fabiani; Santiago Haase; Stephen Carney; Jessica C Gauss; Oren J Becher; Pedro R Lowenstein; Maria G Castro Journal: Neuro Oncol Date: 2020-02-20 Impact factor: 12.300
Authors: Patricia A Baxter; Jack M Su; Arzu Onar-Thomas; Catherine A Billups; Xiao-Nan Li; Tina Young Poussaint; Edward R Smith; Patrick Thompson; Adekunle Adesina; Pete Ansell; Vincent Giranda; Arnold Paulino; Lindsey Kilburn; Ibrahim Quaddoumi; Alberto Broniscer; Susan M Blaney; Ira J Dunkel; Maryam Fouladi Journal: Neuro Oncol Date: 2020-06-09 Impact factor: 12.300
Authors: Sonia Tejada; Kristian Aquilina; John Goodden; Benedetta Pettorini; Conor Mallucci; Marie Lise van Veelen; Ulrich-W Thomale Journal: Childs Nerv Syst Date: 2020-02-04 Impact factor: 1.475
Authors: C Jaimes; S Vajapeyam; D Brown; P-C Kao; C Ma; L Greenspan; N Gupta; L Goumnerova; P Bandopahayay; F Dubois; N F Greenwald; T Zack; O Shapira; R Beroukhim; K L Ligon; S Chi; M W Kieran; K D Wright; T Y Poussaint Journal: AJNR Am J Neuroradiol Date: 2020-05-07 Impact factor: 3.825
Authors: Nicholas A Vitanza; Matt C Biery; Carrie Myers; Eric Ferguson; Ye Zheng; Emily J Girard; Justyna M Przystal; Giulia Park; Alyssa Noll; Fiona Pakiam; Conrad A Winter; Shelli M Morris; Jay Sarthy; Bonnie L Cole; Sarah E S Leary; Courtney Crane; Nicole A P Lieberman; Sabine Mueller; Javad Nazarian; Raphael Gottardo; Mi-Youn Brusniak; Andrew J Mhyre; James M Olson Journal: Neuro Oncol Date: 2021-03-25 Impact factor: 12.300
Authors: Evan D Bander; Jonathan H Sherman; Chetan Bettegowda; Manish K Aghi; Jason Sheehan; Rohan Ramakrishna Journal: J Neurooncol Date: 2021-02-21 Impact factor: 4.130